Daewoong's Nabota tops botulinum toxin exports
Daewoong Pharmaceutical said Tuesday that its botulinum toxin product, Nabota, posted 113.3 billion won ($85.3 million) in sales as of the third quarter this year.
Overseas sales made up 93.5 billion won or 83 percent of the total, the company added.
Nabota's overseas sales have continued growing in recent years, an outcome of Daewoon's global push. The portion reached 61 percent in 2021 and then surged to 77 percent last year.
US sales, in particular, reached 44.5 billion won, making up more than 50 percent of global sales.
“Nabota’s share in the US botulinum toxin market has surged over the last two years. We expect to further boost our share in the future," a Daewoong official said.
Nabota, sold as Jeuveau in the US, made its US debut in 2020 through local partner Evolus’ botulinum toxin treatment program. Nabota currently has around an 11 percent share in the US botulinum toxin market, according to the company.
“Nabota was able to take the lead among Korea’s botulinum toxin products as Daewoong set its plans ahead for its launch in the US and received approval from the US Food and Drug Administration fast,” said Park Seong-soo, vice president of Daewoong Pharmaceutical.
In South Korea, a total of 11 botulinum toxin products have received approval from the government so far, and three additional products are under review.
Daewoong said the company will speed up Nabota launches in European countries, including Germany, Italy and Austria.
The company added it would also make a foray into the Malaysian market soon. In August, Daewoong received sales approval from the National Pharmaceutical Regulatory Agency in Malaysia.
(责任编辑:여행)
下一篇:CHA to expand assistance for buried cultural heritage excavation
- ·Seoul shares open lower on Fed, growth woes
- ·S. Korea’s consumer sentiment turns sour in September: BOK index
- ·Seoul prepares for first major military parade in ten years
- ·S. Korea defeat Japan for 3rd straight men's football gold
- ·홍익표, 체포안 가결파 징계에 “총선 승리 도움 기준으로 판단”
- ·NK sports broadcast labels S. Korea ‘puppets'
- ·S. Korean fencer Oh Sang
- ·[Photo News] Floral Butterfly
- ·Consumption slows down amid high rates, inflation
- ·S. Korean diplomat discusses NK human rights with US envoy
- ·'Apgujeong Box Girl' sparks online debate
- ·Yoon lauds rapid growth of Korean defense industry
- ·NewJeans, Seventeen, BTS win top honors at 2023 MAMA Awards
- ·Yoon, doctors set to clash over medical school quota
- ·S. Korea, US, Japan install trilateral communication hotline amid N. Korea, China challenges
- ·Seoul subway workers vote for strike plan
- ·Celltrion's Zymfentra to make US debut in February
- ·USS Carl Vinson deploys for Indo
- ·Bomb threat causes midnight fuss at Yonsei university
- ·[Contribution] Why hope matters in climate crisis
- ·[Korea Beyond Korea] In Paris, soaring demand for Korean studies yet to be fully met
- ·MBK chairman makes donation to promote Korean art at New York's Met
- ·Industrial output, retail sales, investment all fall in Oct.: data
- ·Over 1,300 rescue workers still traumatized by Itaewon Halloween tragedy
- ·Number of deaths in cycling accidents soars
- ·Reeling from election loss, ruling party picks new leader posts
- ·BM of Kard to return solo with single ‘Lowkey’ this month
- ·이준석, 눈물의 회견…尹대통령 향해 "與 묵언 수행 저주 풀라"